{"id":46531,"date":"2024-02-20T08:00:00","date_gmt":"2024-02-20T08:00:00","guid":{"rendered":"http:\/\/8d4079e5a6b2ac82da415f264553bfab"},"modified":"2024-11-03T15:11:53","modified_gmt":"2024-11-03T15:11:53","slug":"esmo-targeted-anticancer-therapies-congress-2024-26-28-february-paris-france","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/esmo-targeted-anticancer-therapies-congress-2024-26-28-february-paris-france\/","title":{"rendered":"ESMO Targeted Anticancer Therapies Congress 2024, 26-28 February, Paris, France"},"content":{"rendered":"<p>Lugano, Switzerland, 19 February 2024 \u2013 The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care. This event brings together various experts in the early drug development arena, including investigators from academia, investor and regulatory bodies, as well as translational scientists.<\/p>\n<p>The event will be held in Paris, France, between 26-28 February.<\/p>\n<h3>New this year<\/h3>\n<ul>\n<li>Four new special sessions will enrich this year\u2019s scientific <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/session\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">programme<\/a>, with international speakers from the pharmaceutical industry addressing methodological and regulatory challenges in the development and implementation of innovative cancer therapeutics.<br \/>Related content: <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/show\/session\/3\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Session<\/a>&nbsp;on 26 February, 13:45-15:15 CET; Sessions on 27 February, <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/show\/session\/11\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">11:15-12:45 CET<\/a>&nbsp;and <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/show\/session\/17\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">13:45-15:15 CET<\/a>; <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/show\/session\/27\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Session<\/a>&nbsp;on 28 February, 13:30-15:00 CET<\/li>\n<\/ul>\n<h3>Programme highlights<\/h3>\n<ul>\n<li>The role of artificial intelligence, machine learning, and digital technology in early phase research: From uncovering new immunotherapy targets with clinical potential to unveiling new potential targeted therapies&nbsp;<br \/>Related content: <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/show\/session\/20\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">1O<\/a>, <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/show\/session\/6\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">2P, 4P, 5P<\/a>&nbsp;and <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/show\/session\/7\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">session<\/a>&nbsp;on 27 February, 8:00-8:45 CET<\/li>\n<\/ul>\n<ul>\n<li>Novel perspectives on antibody-drug conjugates: new targets, linkers, payloads and combination with other agents&nbsp;<br \/>Related content: <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/show\/session\/23\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Session<\/a>&nbsp;on 28 February, 09:15-10:45 CET<\/li>\n<\/ul>\n<ul>\n<li>ctDNA as promising biomarker to predict the patients\u2019 response to treatment and guide experimental therapeutics in phase I trials<br \/>Related content: <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/show\/session\/20\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">85O, 86O,<\/a> <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/show\/session\/9\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Session<\/a>&nbsp;on 27 February, 09:15-10:45 CET<\/li>\n<\/ul>\n<h3>Award keynote lectures<\/h3>\n<p>The results of more than 110 studies from various parts of the world will be presented and published online as a supplement to <em>ESMO Open<\/em>. The abstract titles can be viewed through the online <a href=\"https:\/\/cslide.ctimeetingtech.com\/tat2024\/attendee\/confcal\/session\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">programme<\/a>.<\/p>\n<h3>Press accreditation<\/h3>\n<p>ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the <a href=\"https:\/\/www.esmo.org\/newsroom\/press-and-media-policies\/esmo-policy-on-press-activities\" class>ESMO Policy on Press Activities<\/a>. To apply for press accreditation, please fill out the form available <a href=\"https:\/\/press-portal.esmo.org\/#\/accreditation?meeting=7474&amp;callbackUrl=https:\/\/www.esmo.org\/newsroom\/esmo-press-office\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">here<\/a>. Requests for press accreditation should be sent by Friday, 23 February. Please be kindly informed that onsite press accreditation will not be available.<\/p>\n<h3>Further information<\/h3>\n<p>ESMO Press Office<br \/><a href=\"mailto:press@esmo.org\" target=\"_blank\" rel=\"noopener noreferrer\" class>press@esmo.org<\/a><\/p>\n<h3>Notes to editors<\/h3>\n<p>Please make sure to use the official name of the meeting in your reports: <strong>ESMO TAT 2024<\/strong> and the official congress hashtag <strong>#ESMOTAT24<\/strong>. Follow it to stay up to date and use it to take part in the conversation on <a href=\"https:\/\/twitter.com\/myESMO\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">X (Twitter)<\/a>, <a href=\"https:\/\/www.linkedin.com\/company\/european-society-for-medical-oncology\/\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">LinkedIn<\/a>, <a href=\"https:\/\/www.instagram.com\/esmo_eur_oncology\/\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Instagram<\/a>, <a href=\"https:\/\/www.facebook.com\/esmo.org\/\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Facebook<\/a><\/p>\n<p><a href=\"https:\/\/www.esmo.org\/newsroom\/press-and-media-hub\/esmo-media-releases\/esmo-targeted-anticancer-therapies-congress-2024-26-28-february-paris-france\">Source<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Lugano, Switzerland, 19 February 2024 \u2013 The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care. This event brings together various experts in the early drug development arena, including investigators from academia, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-46531","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=46531"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46531\/revisions"}],"predecessor-version":[{"id":47116,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46531\/revisions\/47116"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=46531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=46531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=46531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}